We applied FGmRNA profiling to correct gene expression data for the effect of non-genetic and experimental factors on gene expression levels, followed by data-driven prioritization to identify RRM2, MAPK9, and XIAP as new potential therapeutic targets in GBM. The gene discussed is RRM2; the disease is glioblastoma.